Compass Therapeutics (CMPX) Preferred Stock Liabilities (2018 - 2020)

Compass Therapeutics' Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $129.9 million for Q1 2020.

• In Q1 2020, Preferred Stock Liabilities changed 0.0% year-over-year to $129.9 million; the TTM figure through Mar 2020 stood at $129.9 million (changed 0.0% YoY), while the FY2020 annual figure was $129.9 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities came in at $129.9 million for Q1 2020 at Compass Therapeutics, roughly flat from $129.9 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $129.9 million in Q4 2018 to a low of $129.9 million in Q4 2018.
• A 3-year average of $129.9 million and a median of $129.9 million in 2018 frame the typical range for Preferred Stock Liabilities.
• On a YoY basis, Preferred Stock Liabilities climbed as much as 0.0% in 2019 and fell as far as 0.0% in 2019.
• Compass Therapeutics' Preferred Stock Liabilities stood at $129.9 million in 2018, then changed by 0.0% to $129.9 million in 2019, then changed by 0.0% to $129.9 million in 2020.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $129.9 million, $129.9 million, and $129.9 million for Q1 2020, Q4 2019, and Q3 2019 respectively.

Peer Comparison